Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort

被引：0

作者：

Bigaut, K. ^{[1
]}

Fabacher, T. ^{[2
]}

Kremer, L. ^{[1
]}

Ongagna, J. -C. ^{[1
]}

Kwiat-Kowski, A. ^{[3
]}

Sellal, F. ^{[4
]}

Ferriby, D. ^{[5
]}

Courtois, S. ^{[6
]}

Vermersch, P. ^{[7
]}

Collongues, N. ^{[1
]}

Zephir, H. ^{[7
]}

De Seze, J. ^{[1
]}

Outteryck, O. ^{[7
]}

机构：

[1] Hop Univ Strasbourg, Dept Neurol, Strasbourg, France

[2] Hop Univ Strasbourg, Grp Methode Rech Clin, Strasbourg, France

[3] Grp Hop Inst Catholique Lille, Dept Neurol, Hop St Vincent, Lille, France

[4] Hop Civils Colmar, Dept Neurol, Colmar, France

[5] Ctr Hosp Tourcoing, Dept Neurol, Tourcoing, France

[6] Grp Hosp Reg Mulhouse & Sud Alsace, Dept Neurol, Mulhouse, France

[7] Ctr Hosp Reg Univ Lille, Dept Neurol, Lille, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1013

引用

页码：536 / 536

页数：1

共 50 条

[11] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
Agiela, Mabroka I. M.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
[12] Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
Tasset, Inmaculada
Bahamonde, Carmen
Agueera, Eduardo
Conde, Cristina
Cruz, Antonio H.
Perez-Herrera, Aleyda
Gascon, Felix
Giraldo, Ana I.
Ruiz, Maria C.
Lillo, Rafael
Sanchez-Lopez, Fernando
Tunez, Isaac
PHARMACOLOGICAL REPORTS, 2013, 65 (03) : 624 - 631
[13] Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis
Inmaculada Tasset
Carmen Bahamonde
Eduardo Agüera
Cristina Conde
Antonio H. Cruz
Aleyda Pérez-Herrera
Félix Gascón
Ana I. Giraldo
María C. Ruiz
Rafael Lillo
Fernando Sánchez-López
Isaac Túnez
Pharmacological Reports, 2013, 65 : 624 - 631
[14] Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort
Bigaut, Kevin
Fabacher, Thibaut
Kremer, Laurent
Ongagna, Jean-Claude
Kwiatkowski, Arnaud
Sellal, Franois
Ferriby, Didier
Courtois, Sylvie
Vermersch, Patrick
Collongues, Nicolas
Zephir, Helene
De Seze, Jerome
Outteryck, Olivier
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (05) : 729 - 741
[15] Long-term effect of fingolimod on cardiovascular functioning in people with relapsing-remitting multiple sclerosis
Haase, R.
Forberger, C.
Schilling, M.
Piatkowski, F.
Akgun, K.
Rudiger, H.
Ziemssen, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 609 - 610
[16] Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study
Hernandez-Preciado, Martha Rocio
Marquez-Pedroza, Jazmin
Sanchez-Rosales, Nayeli Alejandra
Garcia-Rivera, Jose de Jesus
Kobayashi-Gutierrez, Antonio
Torres-Mendoza, Blanca Miriam
Chavarria-Avila, Efrain
Montano-Serrano, Raul Alejandro
Cortes-Enriquez, Fernando
Mireles-Ramirez, Mario Alberto
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
[17] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
Saida, Takahiko
Hao, Qi
Kanda, Michihiro
Tani, Yumiko
BMC NEUROLOGY, 2023, 23 (01)
[18] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
Takahiko Saida
Qi Hao
Michihiro Kanda
Yumiko Tani
BMC Neurology, 23
[19] Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis
Wiendl, H.
Butzkueven, H.
Trojano, M.
Goodin, D.
Kappos, L.
Desgrandchamps, D.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S248 - S248
[20] Case History Long-Term Treatment of relapsing-remitting MS with Natalizumab
Sievers, Carsten
NERVENHEILKUNDE, 2013, 32 (10) : 786 - 786

← 1 2 3 4 5 →